and immunomodulators. Since then, the first B-cell maturation antigen antibody-drug conjugate, chimeric antigen receptor T-cell therapies, and now bispecific antibodies with multiple mechanisms of action have become available. This enables durable response potential across multiple myeloma treatment lines....
To maximize efficacy and minimize toxicity, bispecific antibodies should target an antigen that is unique and specific to multiple myeloma cells, with minimal expression in other healthy tissues. Currently approved and in- trial BsAbs for MM are directed against B-cell membrane antigen (BCMA), G-...
Bispecific antibodiesClinical trialPodcastThe introduction of novel immunotherapies has transformed the treatment landscape in multiple myeloma (MM). The addition of these agents has significantly improved patient outcomes; however, MM remains largely incurable, with heavily pretreated patients suffering from ...
Keith Stewart, MB, ChB:I want to review the data for bispecific antibodies, or BiTEs—slightly different technologies, but we’ll lump them together for today. Peter, you’ve had some experience with some of these. Do you want to talk us through that? Peter Voorhees, MD:Sure. At LCI [...
In an interview with Targeted Oncology, Prerna Mewawalla discussed the role of bispecific antibodies in multiple myeloma treatment and options to consider before patients reach the relapsed/refractory setting. Prerna Mewawalla, MD The multiple myeloma space is exploding with treatment options for patients...
James Ignatz-Hoover, MD, PhD, discusses the current arsenal of FDA-approved bispecific antibodies in multiple myeloma.
EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma EP: 9.Step-Up Dosi...
Research into bispecific antibodies, which are designed to simultaneously bind two antigens or epitopes, has advanced enormously over the past two decades. Owing to advances in protein engineering technologies and considerable preclinical research efforts, bispecific antibodies are constantly being developed ...
In the past two decades, considerable advances in the treatment of multiple myeloma have led to improved survival rates. However, patients who become refractory to proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies have dismal outcomes, with a median overall survival of...
Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk N, Leleu X, Gallego Perez-Larraya J, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25:...